These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 23811743

  • 1. Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data.
    Cotton M, Cassim H, Pavía-Ruz N, Garges HP, Perger T, Ford SL, Wire MB, Givens N, Ross LL, Lou Y, Sievers J, Cheng K.
    Pediatr Infect Dis J; 2014 Jan; 33(1):57-62. PubMed ID: 23811743
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.
    Fortuny C, Duiculescu D, Cheng K, Garges HP, Cotton M, Tamarirt DP, Ford SL, Wire MB, Givens N, Ross LL, Lou Y, Perger T, Sievers J.
    Pediatr Infect Dis J; 2014 Jan; 33(1):50-6. PubMed ID: 23811744
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.
    Gathe JC, Ive P, Wood R, Schürmann D, Bellos NC, DeJesus E, Gladysz A, Garris C, Yeo J.
    AIDS; 2004 Jul 23; 18(11):1529-37. PubMed ID: 15238771
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
    Ruane PJ, Luber AD, Wire MB, Lou Y, Shelton MJ, Lancaster CT, Pappa KA, COL10053 Study Team.
    Antimicrob Agents Chemother; 2007 Feb 23; 51(2):560-5. PubMed ID: 17088488
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA, Hendrix CW, Barditch-Crovo P, Parsons T, Khan W, Parish M, Radebaugh C, Carson KA, Pakes GE, Qaqish R, Flexner C.
    Antivir Ther; 2007 Feb 23; 12(6):963-9. PubMed ID: 17926651
    [Abstract] [Full Text] [Related]

  • 11. Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients.
    Barbour AM, Gibiansky L, Wire MB.
    J Clin Pharmacol; 2014 Feb 23; 54(2):206-14. PubMed ID: 25272370
    [Abstract] [Full Text] [Related]

  • 12. Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir.
    Corbett AH, Patterson KB, Tien HC, Kalvass LA, Eron JJ, Ngo LT, Lim ML, Kashuba AD.
    Antimicrob Agents Chemother; 2006 Aug 23; 50(8):2756-61. PubMed ID: 16870769
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment.
    Pérez-Elías MJ, Morellon ML, Ortega E, Hernández-Quero J, Rodríguez-Torres M, Clotet B, Felizarta F, Gutiérrez F, Pineda JA, Nichols G, Lou Y, Wire MB.
    Antimicrob Agents Chemother; 2009 Dec 23; 53(12):5185-96. PubMed ID: 19667283
    [Abstract] [Full Text] [Related]

  • 14. Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II).
    Parks DA, Jennings HC, Taylor C, Pakes GE, Acosta EP.
    HIV Clin Trials; 2009 Dec 23; 10(3):160-7. PubMed ID: 19632955
    [Abstract] [Full Text] [Related]

  • 15. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
    Luber AD, Condoluci DV, Slowinski PD, Andrews M, Olson K, Peloquin CA, Pappa KA, Pakes GE, COL104422 Study Team.
    HIV Med; 2010 Mar 23; 11(3):193-9. PubMed ID: 19863619
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir.
    Shelton MJ, Wire MB, Lou Y, Adamkiewicz B, Min SS.
    Antimicrob Agents Chemother; 2006 Mar 23; 50(3):928-34. PubMed ID: 16495253
    [Abstract] [Full Text] [Related]

  • 17. Study APV20002: Safety and Efficacy Results Through Week 684 for Pediatric Participants Living with HIV-1 Treated with Ritonavir-Boosted Fosamprenavir Oral Solution-Based Antiretroviral Therapy.
    Ross LL, Cotton MF, Cassim H, Garges HP, van Dijkman SC, Morarji K, Karthika S, Danehower S, Radford J, Butcher D.
    AIDS Res Hum Retroviruses; 2024 Oct 23; 40(10):606-613. PubMed ID: 38973446
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.
    Vourvahis M, Plotka A, Mendes da Costa L, Fang A, Heera J.
    Antimicrob Agents Chemother; 2013 Dec 23; 57(12):6158-64. PubMed ID: 24080663
    [Abstract] [Full Text] [Related]

  • 19. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics.
    Shelton MJ, Ford SL, Borland J, Lou Y, Wire MB, Min SS, Xue ZG, Yuen G.
    J Acquir Immune Defic Syndr; 2006 May 23; 42(1):61-7. PubMed ID: 16639341
    [Abstract] [Full Text] [Related]

  • 20. Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.
    Boffito M, Dickinson L, Hill A, Back D, Moyle G, Nelson M, Higgs C, Fletcher C, Gazzard B, Pozniak A.
    J Acquir Immune Defic Syndr; 2004 Nov 01; 37(3):1376-84. PubMed ID: 15483467
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.